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Background: Life expectancy is increasing continuously, which increases the
likelihood of developing dementia or cancer. Both dementia and cancer are serious
conditions that give manifold symptoms. The interaction of these conditions is
however complex and less explored. Objectives: The aim of this study was to identify
the prevalence of cancer and differences regarding neuropsychiatric symptoms
(NPS) and medication among nursing home (NH) patients with and without dementia
and cancer. Methods: This is a cross-sectional study of Norwegian NH patients
(N=1825). Participants were categorized according to degree of dementia (Clinical
Dementia Rating 9 1) and cancer diagnoses. Differences in NPS and other symptoms,
as well as the use of medication, were explored. Results: Eighty-four percent of NH
patients had dementia, and 5.5% had comorbid dementia and cancer. Patients with
comorbid dementia and cancer received significantly more analgesics compared with
patients without cancer but with dementia (PG .05). Compared with patients without
dementia but with cancer, patients with comorbid dementia and cancer had
significantly more NPS, including sleep disturbances and agitation. Conclusions:
Patients with comorbid dementia and cancer receive more analgesics than patients
with dementia but still display more agitation and sleep disturbances than patients with
cancer and patients with neither dementia nor cancer, suggesting that symptoms may
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not be treated adequately. Implications for Practice: The results indicate a
considerable strain for patients with comorbid dementia and cancer and highlight
essential challenges for the clinician who is responsible for treatment and care. Nurses
should pay attention to agitation and sleep disturbances among patients with comorbid
dementia and cancer.
L
ife expectancy is continuously increasing worldwide,
and the likelihood of developing dementia is thereby
growing dramatically.1 Dementia, of which the most
common cause is Alzheimer’s disease, is an incurable and pro-
gressive condition. It affects 35 million people worldwideVa
number expected to almost double in the next 2 decades.2,3 In
general, dementia results in the decline of the person’s cognition
and physical function. Up to 90% of people with dementia ex-
perience neuropsychiatric symptoms (NPS), such as agitation,
depression, and delusion, during the course of their disease.4 In
total, 77000 Norwegians are affected by this disease,5 and
approximately 14% of Norwegians older than 80 years receive
institutional care.6
Cancer diseases affect approximately 10 million people in
Europe,7 and 30000 new cases annually are expected.8 As a
result of the demographic development, the prevalence is
expected to double during the next 10 years.9 By the end of 2014,
242398 Norwegians were registered with a cancer diagnosis,
and the disease was the cause of death for 10971 people.10 In
Norway, 3 of 4 cancer cases are diagnosed in those older than
60 years,10 and a quarter of all terminal patients with cancer die
in a nursing home (NH).11 Previous studies indicate that from
14% to 26% of Norwegian NH patients are given a diagnosis of
cancer,12 and international studies show that approximately 5%
were receiving active cancer treatment when being admitted to an
institution.13 It is unknown how many develop cancer during the
time they live in an NH and how this is discovered and treated.
The likelihood of developing comorbid dementia and cancer
increases with age. Cancer symptoms are potentially more onerous
for people with both conditions because they are no longer able
to give a valid self-reportVa prerequisite for adequate treatment.14
As suggested by symptom science, the management of symptoms
needs to be based on an understanding of the individual, the
condition, and the context in which the individual resides.15
Ideally, the assessment of cancer-related pain and symptoms
should be based on the individual’s self-report with subsequent
administration of analgesics and appropriate symptom man-
agement.16 However, people with dementia express their pain
in ways that are different from those without cognitive impairment,
leading to agitation17,18 and depression.19,20 Furthermore, previ-
ous studies show that sleep disturbances are related to the presence
of untreated pain21,22 and to depression.23,24 In light of recent
research, which indicates that benzodiazepines have no effect on
sleep time between users and nonusers,25 there is a need for aware-
ness around these circumstances because they can contribute to
potentially meaningless treatment and widespread use of
psychotropic drugs.26
In a recent review, our group summarized the evidence on
cancer-related symptoms among NH patients11 and highlighted
11 studies, which together confirmed high prevalence of pain
and reduced analgesic drug prescription in NH patients with
cancer. Only 1 smaller study (n=48) included patients with
comorbid dementia and cancer, and this study found that
people with severe dementia received less opioids and displayed
less pain behavior compared with patients with mild cognitive
impairment.27 Another study by Monroe et al28 found that
patients with comorbid dementia and cancer were more likely
to receive an opioid if they were enrolled in hospice. However,
patients enrolled in hospice were more cognitively intact.
The overall purpose of the study is to investigate comorbid
dementia and cancer among NH residents, with a particular
emphasis on NPS and the medication thereof. The study has
the following research objectives: (1) to investigate the prevalence
of cancer among NH patients with and without dementia and (2)
to compare patients with comorbid dementia and cancer with
those without, with regard to the prevalence of NPS such as
agitation, depression, and sleep disturbances and the daily use of
medication, including analgesic drug prescription.
n Method
Design, Setting, and Procedure
The study builds on secondary analyses of a multicenter, cross-
sectional study including 64 NHs, located in urban and rural
areas in 5 of 19 counties of Norway. The data set includes
standardized interviews with NH staff, as well as information
from patients’ medical records. The organization of the setting
and the participants of the study have been previously described
by Helvik et al29 wherein this data set was used alongside data
from 2004. In brief, Norway has around 34000 long-term NH
patients,30 and the jurisdiction for public healthcare services is
the responsibility of the municipalities. In the process of gaining
a representative sample of small, medium-sized, and large
municipalities from both urban and rural areas, 49 municipal-
ities were approached, and the sample of NHs was selected.
The study was conducted from June 2010 to November
2011. All patients in the NHs were screened for inclusion, and
all patients who had lived in the NH for at least 2 weeks were
eligible. Project nurses were responsible for data collection.
Before data collection, they participated in a 2-day session on
the use of mapping instruments and standardized interviews, as
well as on the purpose of the study. Data collection involved
registering information from each patient’s medical record, as
well as performing standardized interviews with the patient’s
primary caregiver, who served as a proxy for the patient, regardless
of the patient’s degree of cognitive impairment.
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Measurements
We classified the patient’s level of dementia by the Clinical
Dementia Rating (CDR) scale (range, 0Y3). The instrument
consists of 6 categories with scores for no dementia of 0, possible
dementia of 0.5, and mild, moderate, and severe dementia of 1,
2, and 3, respectively. The cutoff point for the presence of
dementia is CDR of 1 or greater. The CDR scoring algorithm
weights memory as the primary domain and the other domains
as secondary.31 Good validity and reliability of the scale have
been reported (overall . = 0.62).32Y34
Cancer diagnoses were collected from patients’ records and
coded by means of the International Classification of Diseases,
Tenth Revision.35 Ongoing medical treatment from patients’
records was coded by the Anatomical Therapeutic Chemical
(ATC) SystemVan international system for the classification of
drugs.36 We divided analgesics into 3 groups: (1) peripheral
(ATC, N02B), (2) opioids (ATC, N02A), and (3) nonsteroidal
anti-inflammatory drugs, namely, anti-inflammatory and anti-
rheumatic drugs (ATC, M01). We similarly collected data on
the following psychotropic drugs: antidepressants (ATC,
N06A), anxiolytic drugs (ATC, N05B), sedatives (ATC,
N05C), antidementia drugs (ATC, N06D), and antipsychotics
(ATC, N05A).
We assessed NPS related to dementia using the Neuropsy-
chiatric Inventory-Nursing Home version (NPI-NH).37 The
NPI-NH maps12 NPS associated with dementia: delusions,
hallucinations, dysphoria/depression, anxiety, agitation/aggression,
euphoria, disinhibition, irritability/lability, apathy, aberrant
motor behavior, nighttime behavior, and appetite disturbances/
eating change (all judged as no/yes). Each symptom was scored
for frequency (score, 1Y4) and severity (score, 1Y3), and a product
score (0Y12) was calculated thereof for each symptom. In this
study, we used a previously identified underlying 4-factor
structure,38 in which items are clustered into subsyndromes for
agitation (agitation and irritability), affective symptoms (depres-
sion and anxiety), and psychosis (hallucination and delusions),
whereas apathy is analyzed as a single symptom. In addition to
the use of these NPS factors, sleep disturbances were identified
using the nighttime behavior item from the NPI-NH. Scores of
1 or higher suggest impaired sleep, and in accordance with
previous studies, anyone scoring higher than or equal to 4 on
this item was judged as having clinically significant sleep
disturbances.39
We used the Cornell Scale for Depression in Dementia (CSDD)
to measure depression, an instrument that is found to be a reliable
measure for depression in people with dementia (Cronbach’s
! = .84).40,41 We used the General Medical Health Rating
(GMHR) to assess patients’ degree of somatic illness. It is a reliable
and valid measure, with 1 item comprising 4 categories, which
assesses medical comorbidity (weighted . = 0.93).42 The 4
categories were excellent, good, fair, and poor. The rating was
performed based on all available medical information. In
addition, we used the Physical Self-Maintenance Scale (PSMS),
a reliable measure of patients’ level of function with regard to
activities of daily living. A high score indicates a lower level of
functioning.43,44
Statistical Analyses
We calculated the mean, standard deviation (SD), and range for
patient characteristics (number of diagnoses, regular drugs, and
analgesics) and calculated the product score for the NPI-NH
and its 4 subclusters and sum scores for the CSDD and the
PSMS. For the GMHR, we created a binary variable from the 4
categories of the scale simply reflecting good or bad health.
Patients who had excellent or good health were recorded as
‘‘good,’’ whereas those with fair or poor health were recorded as
‘‘bad.’’ For all variables, means were compared across patient
groups, and the statistical significance of the differences was
tested by means of analyses of variance and logistic regressions
for continuous and categorical variables, respectively. In the
analyses, we divided the final sample into 4 groups, which we
refer to throughout the text and tables in the following way:
patients with comorbid dementia and cancer (COMORBID),
patients with cancer but without dementia (CANCER), patients
with dementia but without cancer (DEMENTIA), and patients
who have neither dementia nor cancer (NEITHER).
Finally, we conducted a multiple logistic regression inves-
tigating the likelihood of analgesic drug prescription to inves-
tigate the characteristics associated with the use of analgesics,
while controlling for other variables. The dependent variable
was a categorical variable indicating whether the patient received
analgesics regularly. The independent variables were the fol-
lowing: cancer, dementia, comorbidity, GHMR, PSMS,
CSDD, NPI-NH, regular drugs, use of sedatives, age, and
gender. We conducted the statistical analyses in IBM SPSS
Statistics 22.
Ethical Approval
We obtained verbal and written information in direct conver-
sation with the patient (if possible) and his/her legal guardian,
usually a family member or an advocate, in accordance with
local law. Depending on the patient’s ability to give consent, the
patient or next of kin made the decision of participation in the
study after we explained the aims and protocol of the study. The
Regional Committee for Medical and Health Research Ethics
(REC West) in Norway approved the study (REC number
2010/1894).
n Results
There were 2385 residents eligible for inclusion. From this
sample, 560 patients were excluded for the following reasons:
the patient or next of kin declined participation (n=423),
serious somatic illness or terminal conditions (n=33), death
before data collection (n=17), leaving the NH before assessment
(n=1), and either missing data or unlisted reasons (n=53). In
addition, 33 patients were excluded from the analyses because of
the lack of CDR scores. The final sample was composed of 1825
participants. Seventy-one percent of the participants were
women, and the mean (SD) age was 85.1 (8.04) years. Baseline
clinical characteristics are reported in Table 1.
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Prevalence of Dementia and Cancer Among
NH Patients
The total sample consisted of 1825 patients. One hundred
thirty-three patients (7.3%) had cancer, of which 100 patients
had comorbid dementia and cancer (5.5%) and 33 patients
had a cancer diagnosis but no dementia (1.8%). Thus, the
prevalence of cancer is significantly higher among patients
without dementia than among those with dementia (PG .01).
Most common was breast cancer for women (45%) and prostate
cancer for men (31%). Colorectal cancer was the second most
common cancer diagnosis for both genders (17% of cancer cases
overall). Cognitive impairment consistent with dementia
(CDRQ1) was found in 1535 patients (84%); 29% had
moderate dementia, and 36% had severe dementia. The most
frequent diagnoses from the NH medical record were unspecified
dementia and Alzheimer’s disease (29% and 12%, respectively),
hypertension (27%), and apoplexia cerebri (15%). Regarding our
first research objective, our findings reveal higher prevalence of
cancer among patients without dementia than among those with
dementia. Compared with cancer prevalence in NHs docu-
mented in previous research, the prevalence of cancer in this
sample is quite low.
Comparison of NPS and Medication Use for the
Different Patient Groups
Compared with CANCER patients (n=33), COMORBID
patients (n=100) displayed more NPS based on NPI-NH
sum score (PG .01) for the agitation cluster score (PG .05) and
the apathy item score (PG .05). These individuals also dis-
played worse physical function (PG .01) and had significantly
more sleep disturbances (PG .01). We found no differences
between the groups regarding the use of medication or in socio-
demographic characteristics (see Table 2).
Compared with DEMENTIA patients (n=1435), COMOR-
BID patients had significantly more diagnoses (PG .01) and
received more analgesics (PG .05), in particular, opioids (PG .05).
There were no other significant differences between the 2 groups
(see Table 2).
Compared with NEITHER patients (n=257), COMORBID
patients had significantly reduced physical function and more
NPS as measured by the NPI-NH sum score and agitation and
psychosis cluster scores (PG .01) (see Table 2). Similarly, they had
higher scores for singular behavioral disturbances such as apathy,
sleep disturbances, and depression assessed by the CSDD. They
also had more comorbidity and worse somatic health according to











Age, y 85.20 (7.99) 86.03 (7.30) 82.70 (9.50) 85.29 (7.72) 84.70 (9.36)
Female, % 71 68 76 71 68
Diagnoses 3.04 (1.71) 3.83 (1.85) 3.76 (1.90) 2.94 (1.65) 3.17 (1.84)
Bad health, % 44 54 35 45 37
Depression 4.97 (4.80) 5.83 (5.36) 3.61 (3.72) 5.34 (4.86) 2.86 (3.70)
Level of function 17.53 (5.36) 18.18 (5.18) 13.88 (5.16) 18.14 (5.20) 14.33 (5.08)
Neuropsychiatric symptoms 18.48 (19.46) 19.82 (18.40) 6.85 (7.73) 20.70 (19.94) 7.01 (12.44)
Agitation cluster 5.95 (8.23) 6.38 (8.22) 1.61 (3.56) 6.73 (8.59) 1.95 (4.43)
Psychosis cluster 2.68 (5.03) 2.57 (5.27) 0.73 (2.61) 3.08 (5.28) 0.73 (2.61)
Affective cluster 3.47 (5.15) 3.18 (4.84) 2.03 (3.57) 3.76 (5.32) 2.13 (4.13)
Apathy cluster 1.87 (3.32) 2.39 (3.76) 0.45 (1.54) 2.10 (3.44) 0.60 (2.04)
Sleep disturbances, % 17.6 19 9.1 19.4 8.6
Regular drugs 6.93 (3.25) 6.66 (3.02) 8.09 (2.98) 6.67 (3.11) 8.32 (3.73)
Analgesics, % 55 68 58 54 53
Peripheral analgesics, % 48 56 45 48 47
Opioids, % 23 35 36 22 25
NSAIDS, % 4 3 3 4 5
Antidepressants, % 37 38 30 37 35
Anxiolytic agents, % 22 21 24 21 28
Sedatives, % 31 30 48 29 39
Antidementia drugs, % 16 16 3 18 5
Antipsychotics, % 17 15 6 18 14
Each column describes means and SDs (in parentheses) for the full sample, as well as for the 4 subgroups: COMORBID (patients with comorbid dementia and cancer),
CANCER (patients with only cancer), DEMENTIA (patients with only dementia), and NEITHER (patients with neither dementia nor cancer).
Bad health refers to the percentage of patients with bad health as measured by the General Medical Health Rating. Depression refers to the sum score for the Cornell
Scale for Depression in Dementia. Level of function refers to the sum score for the Physical Self-Maintenance Scale. Neuropsychiatric symptoms refer to the product
score for the Neuropsychiatric Inventory-Nursing Home Edition.
Abbreviations: COMORBID, patients with comorbid dementia and cancer; CANCER, patients with only cancer; DEMENTIA, patients with only dementia;
NEITHER, patients with neither dementia nor cancer; NSAIDS, nonsteroidal anti-inflammatory drugs.
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GMHR. COMORBID patients received less medication (PG .01)
but more analgesics (PG .05), than did NEITHER patients.
The regression model predicting the likelihood of using anal-
gesics was statistically significant (PG .001) and explained 21.9%
(Nagelkerke R2) of the variation in analgesic use. As shown in
Table 3, the independent variables that were statistically signi-
ficant were age, gender, use of sedatives, regular drugs, PSMS,
CSDD, and cancer. The highest odds ratio was 1.974 for cancer.
That is, patients with cancer were almost twice as likely to receive
analgesics regularly as were patients without cancer. Regarding our
second research objective, there is significantly a higher prevalence
of NPS among COMORBID patients than among CANCER
and NEITHER patients, but there is no significant difference be-
tween COMORBID and DEMENTIA patients. Furthermore,
analgesic use is significantly more common among COMORBID
patients than among DEMENTIA or NEITHER patients, but
there is no difference between COMORBID and CANCER patients.
n Discussion
Our study found a 7.3% prevalence of cancer among all patients.
Comorbid dementia and cancer were found among 5.5%, whereas
1.8% had only a cancer diagnosis. Compared with CANCER
patients, COMORBID patients displayed significantly more
NPS, such as agitation, depression, and sleep disturbances, as
well as lower function levels regarding daily activities. COMOR-
BID patients also received more analgesics, especially opioids,
compared with CANCER and NEITHER patients.
The overall burden of the comorbid dementia and cancer
group was even more evident when we compared COMORBID
patients with people with neither cancer nor dementia:
COMORBID patients were significantly reduced in their
physical function and had increased intensity of NPS, such as
agitation, psychosis, apathy, and depression, combined with
worse overall health conditions. Interestingly, COMORBID
patients received less medication, than did NEITHER patients,
but more analgesics.
Comorbid Dementia and Cancer
To our knowledge, few studies have investigated the comorbidity
of dementia and cancer in NH patients. The study by Monroe
et al27 indicated that patients with severe Alzheimer’s disease
and cancer have fewer pain behaviors and found severe Alzheimer’s
disease to be negatively associated with total opioid medication.













Age, y 3.33 j0.74 1.33 j2.59
Female, % 8 3 0 j5
Diagnoses j0.07 0.89a 0.66a 0.82a
Bad health, % 19 9 17b j10
Depression 2.22 0.49 2.97a j1.73
Level of function 4.30a 0.04 3.85a j4.26a
Neuropsychiatric symptoms 12.97a j0.88 12.81a j13.85a
Agitation cluster 4.77b j0.35 4.43a j5.12a
Psychosis cluster 1.84 j0.51 1.84a j2.35b
Affective cluster 1.15 j0.58 1.05 j1.73
Apathy cluster 1.94b 0.29 1.79a j1.65b
Sleep disturbances, % 9.9a j0.4 10.4a j10.3
Regular drugs j1.43 j0.01 j1.66a 1.42
Analgesics, % 10 14b 15b 4
Peripheral analgesics, % 11 8 9 j3
Opioids, % j1 13b 12b 14
NSAIDS, % 0 j1 j2 j1
Antidepressants, % 8 1 3 j7
Anxiolytic agents, % j3 0 j7 3
Sedatives, % j18 1 j9 19
Antipsychotics, % 9 j3 1 j12
The table shows differences in mean scores between the 4 patient groups (COMORBID, CANCER, DEMENTIA, and NEITHER) for each of the variables outlined in
Table 1. For instance, the column ‘‘Difference Between COMORBID and CANCER’’ shows the difference in mean scores between the group with comorbid dementia
and cancer (COMORBID) and the group with cancer only (CANCER). Positive values indicate that the former group has the higher mean score, whereas negative
values indicate that the latter group has the higher mean score.
Depression refers to differences in the sum score for the Cornell Scale for Depression in Dementia. Level of function (daily activities) refers to differences in the sum score
for the Physical Self-Maintenance Scale. Neuropsychiatric symptoms refer to differences in the product score for the Neuropsychiatric Inventory-Nursing Home Edition.
Abbreviations: CANCER, Patients with only cancer; COMORBID, Patients with comorbid dementia and cancer; DEMENTIA, Patients with only dementia;
NEITHER, Patients with neither dementia nor cancer; NSAIDS, nonsteroidal anti-inflammatory drugs.
aPG .01.
bPG .05.
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Another study by Monroe et al28 found an association between
hospice enrolment and more opioid pain treatment among
patients with dementia and terminal cancer. However, no patients
with severe dementia and cancer were admitted to hospice.28 The
study highlights that patients with severe dementia and cancer
are at a great risk of having untreated advanced cancer pain
because they are no longer able to account for their suffering.
The results of this study indicated that COMORBID patients
have increased prevalence of NPS, including sleep disturbances,
and reduced level of function with regard to activities of daily
living compared with NEITHER and CANCER patients. How-
ever, COMORBID patients received more analgesics than
DEMENTIA patients but displayed significantly more agitation
than did CANCER and NEITHER patients. This could indicate
that COMORBID patients experienced more pain compared
with CANCER and NEITHER patients. However, there is no
significant difference in NPS between COMORBID and
DEMENTIA patients, and we do not have a measure of pain in
our study. Thus, these findings should be interpreted with caution
because it could be that the dementia is the source of the association.
Today, approximately 5550 patients with comorbid demen-
tia and cancer are living in Norway, and the number is expected
to increase rapidly. The results of our study provide important
information for clinicians in their decision-making process
regarding treatment and care for these individuals. Our results
may support previous studies that showed that untreated pain is
still common among NH patients with cancer.45Y47 To meet
these challenges, pain management methods of high quality are
necessary and should be used. In light of this, it is alarming that
recent findings show that, even when pain is identified through
proper methods, people with cognitive impairment still do not
receive pain treatment.47
Previous studies indicate that approximately 24% of people
with cancer die in an NH.11 From the perspective of symptom
science, the treatment for such patients should be informed by
the patient’s symptom experience, relevant management strat-
egies thereof, and measureable outcomes of the treatments.15 To
optimize care for dying adults in the last days of life, the National
Institute for Health and Care Excellence recently published
guidelines that give an evidence-based approach for all healthcare
professionals involved in the care of a person who is nearing
death.48 Recommendations highlight the need for advanced
care planning and assessment and treatment of pain and
distressing symptoms. It is noteworthy that the care and treatment
for dying people with dementia are not yet mentioned in this
important document.
Interestingly, we did not find differences in NPS between
COMORBID and DEMENTIA patients. Patients with comorbid
dementia and cancer did however receive more analgesics than
DEMENTIA patients, and the lack of differences in NPS could
thus indicate that this treatment is somewhat effective in the
COMORBID group. However, COMORBID patients expressed
more potentially pain-related behavior such as agitation and
sleep disturbance compared with CANCER patients. This is of
key importance because it highlights the particularly vulnerable
position of patients with comorbid dementia and cancer.
Our study reveals a cancer prevalence of 7.3% among NH
patients, which is somewhat lower than previous estimates of 14%
to 26%.11 Results are closer to reports from the United States,
wherein studies revealed cancer prevalence among NH patients
varying from 4% to 14%.13 It is beyond the scope of this study
to explore the cause of the difference in cancer prevalence between
people with and without dementia. However, previous research
indicated that frailty status is associated with decreased cancer
incidence.49 Another interesting aspect is that cancer and cancer
treatment on its own can lead to cognitive impairment, which
highlights the need for more knowledge and guidelines about
the particularities of this group and how it should be treated.50
Depression and Sleep Disturbances Among
People With Comorbid Dementia and Cancer
COMORBID patients also had higher CSDD scores than did
NEITHER patients. There was, however, no difference between
COMORBID and DEMENTIA patients, suggesting that
dementia is the source of the association. Depression is asso-
ciated with pain (pain-depression dyad), although the interac-
tion between the phenomena is poorly understood.19,20 As
shown in the regression analyses, depression is associated with
the use of analgesics, thus suggesting that patients who expe-
rience depression are more likely to receive such medication.
However, the predictor with the highest odds ratio in the
regression is cancer. This suggests a need for further investiga-
tion into the relationship between pain and depression: could,
for instance, depression be a result of pain, in this case, cancer-
related pain? This could be a fruitful topic for further research.
Table 3 & Multiple Logistic Regression Predicting
the Likelihood of Using Analgesics
OR SE P
Cancer 1.974 0.219 .002a
Dementia 1.000 0.158 .998
Comorbidity 1.001 0.034 .973
General medical health 1.206 0.127 .141
Level of function (daily activities) 1.065 0.012 .000a
Depression 1.035 0.016 .035b
Neuropsychiatric symptoms 1.004 0.003 .352
Regular drugs 1.261 0.021 .000a
Use of sedatives 0.776 0.124 .041b
Age, y 1.047 0.007 .000a
Gender, male 0.624 0.120 .000a
R2 0.219
The table shows a multiple logistic regression predicting the likelihood of
using analgesics. The binary variable analgesics (yes/no) is the dependent
variable. The independent variables are listed in the first column. The model
was statistically significant: #2(11, N= 1825)= 300.4, PG .001, Nagelkerke
R2 = 21.9%. Significant P values are shown in boldface, with PG .01 indicated
by the footnote letter a and PG .05 with the footnote letter b.
General medical health refers to the percentage of patients with bad health as
measured by the General Medical Health Rating. Depression refers to the
sum score for the Cornell Scale for Depression in Dementia. Level of
function (daily activities) refers to the sum score for the Physical
Self-Maintenance Scale. Neuropsychiatric symptoms refer to the product
score for the Neuropsychiatric Inventory-Nursing Home Edition.
Abbreviations: OR, odds ratio; SE, standard error.
aPG .01.
bPG .05.
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Furthermore, COMORBID patients had more sleep distur-
bances than did CANCER and NEITHER patients. This
indicates that dementia is also the source of this association and
implies that having comorbid dementia and cancer potentially
can give sleep-related symptoms that are more burdensome.
Our results also show a negative association between the use of
sedatives and the use of analgesics, indicating that, if patients
receive sedatives, they are less likely to be treated with analgesics.
This is of interest because recent research indicates that intense
anxiety and agitation are associated with sedative-hypnotic use.51
Because agitation may be an expression of untreated pain among
people with dementia,17,18 our results may indicate that some
people with comorbid dementia and cancer are given sedatives
instead of pain treatment.
Limitations
The main limitation of this study is the lack of a validated pain
assessment instrument, which could have been used before and
after pain treatment was initiated. Thus, we are not able to
demonstrate the efficacy of analgesic treatment on pain intensity
or to analyze how pain and symptom management affected
related symptoms. For this reason, further research should be
initiated, or alternatively, longitudinal data should be collected
that allow for research on the relationship between treatment
and patient characteristics. Another challenge is that there is
potential for systematic differences between patients declining
inclusion and the final sample, but our data do not allow us to
investigate this. There is also a significant difference in sample
sizes between the 4 patient groups. A third limitation is that the
patients do not have a confirmed diagnosis of dementia. However,
good validity and reliability of the CDR scale have been reported,
and it therefore serves as a good substitute for a diagnosis. Our
data do not reveal the cancer stage and actual cancer treatment
and do not distinguish between current and historical diagnoses
of cancer, that is, patients who already have received successful
treatment of cancer. This may interfere with the analyses of
DEMENTIA and CANCER patients. However, earlier studies
indicated that approximately 5% of patients with cancer in NH
were receiving active cancer treatment at the point of admission.13
n Conclusions and Implications
for Practice
Our study reveals relatively low cancer prevalence in our sample,
yet significantly higher prevalence of cancer among patients with
dementia than among those without. Although we find higher
levels of NPS among COMORBID patients than among
CANCER and NEITHER patients, there are no significant dif-
ferences in NPS between COMORBID and DEMENTIA
patients. Similarly, we find significantly higher use of analgesics
for COMORBID patients than for DEMENTIA and NEITHER
patients but no significant difference between COMORBID
and CANCER patients.
The fact that COMORBID patients receive more analgesics
than DEMENTIA patients, but still display more agitation and
sleep disturbances than CANCER and NEITHER patients,
raises the question of whether they receive adequate treatment.
The lack of pain assessment in our study renders us unable to
provide further evidence on this relationship.
Because COMORBID patients are often no longer able to
give a valid self-report, a prerequisite for adequate treatment,
our results suggest that healthcare professionals working at NHs
should pay close attention to this patient group. Furthermore, our
results highlight the importance of identifying patients at risk for
developing sleep disturbances and other types of NPS. This could
include screening of NPS using validated tools, in addition to the
active use of pain assessment tools to optimize treatment.
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